PMID- 24557418
OWN - NLM
STAT- MEDLINE
DCOM- 20150806
LR  - 20221207
IS  - 1436-3305 (Electronic)
IS  - 1436-3291 (Print)
IS  - 1436-3291 (Linking)
VI  - 18
IP  - 1
DP  - 2015 Jan
TI  - Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable 
      locally advanced or metastatic gastric or gastroesophageal junction cancer: 
      randomized, double-blind, phase III study (AVATAR study).
PG  - 168-76
LID - 10.1007/s10120-014-0351-5 [doi]
AB  - BACKGROUND: In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab 
      did not significantly improve overall survival (OS) versus fluoropyrimidine and 
      cisplatin plus placebo in patients with advanced gastric cancer. Geographic 
      differences in efficacy were observed in AVAGAST, but the study only included 12 
      Chinese patients. AVATAR, a study similar in design to AVAGAST, was a randomized, 
      double-blind, phase III study conducted in Chinese patients with advanced gastric 
      cancer. METHODS: Patients more than 18 years of age with gastric adenocarcinoma 
      were randomized 1:1 to capecitabine-cisplatin plus either bevacizumab or placebo. 
      The primary endpoint was OS; secondary endpoints included progression-free 
      survival (PFS) and safety. RESULTS: In total, 202 patients were included (placebo 
      n = 102; bevacizumab n = 100). Baseline characteristics were well balanced. The 
      primary analysis result did not show a difference in OS for the bevacizumab arm 
      compared to the placebo arm [hazard ratio, 1.11 (95% CI, 0.79-1.56); P = 0.5567]. 
      Median PFS was also similar in both arms. Bevacizumab plus capecitabine-cisplatin 
      was well tolerated. Grade 3-5 adverse events (AEs) occurred in 60% of 
      bevacizumab-treated and 68% of placebo-treated patients, respectively. Grade 3-5 
      AEs of special interest with bevacizumab occurred in 8% of bevacizumab-treated 
      patients and 15% of placebo-treated patients, mainly grade 3-5 hemorrhage 
      (bevacizumab 4%, placebo 12%). CONCLUSIONS: Addition of bevacizumab to 
      capecitabine-cisplatin in Chinese patients with advanced gastric cancer did not 
      improve outcomes in AVATAR. There was no difference in OS between the two arms 
      and PFS was similar in both arms. Safety findings were as previously experienced 
      with bevacizumab, including AVAGAST; no new safety signals were reported.
FAU - Shen, Lin
AU  - Shen L
AD  - Peking University Cancer Hospital and Institute, No 52 Fucheng Road, Haidian 
      District, Beijing, China, Lin100@medmail.com.cn.
FAU - Li, Jin
AU  - Li J
FAU - Xu, Jianming
AU  - Xu J
FAU - Pan, Hongming
AU  - Pan H
FAU - Dai, Guanghai
AU  - Dai G
FAU - Qin, Shukui
AU  - Qin S
FAU - Wang, Liwei
AU  - Wang L
FAU - Wang, Jinwan
AU  - Wang J
FAU - Yang, Zhenzhou
AU  - Yang Z
FAU - Shu, Yongqian
AU  - Shu Y
FAU - Xu, Ruihua
AU  - Xu R
FAU - Chen, Lei
AU  - Chen L
FAU - Liu, Yunpeng
AU  - Liu Y
FAU - Yu, Shiying
AU  - Yu S
FAU - Bu, Lilian
AU  - Bu L
FAU - Piao, Yongzhe
AU  - Piao Y
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140221
PL  - Japan
TA  - Gastric Cancer
JT  - Gastric cancer : official journal of the International Gastric Cancer Association 
      and the Japanese Gastric Cancer Association
JID - 100886238
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adenocarcinoma/drug therapy/mortality/pathology
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
MH  - Asian People
MH  - Bevacizumab
MH  - Capecitabine
MH  - Cisplatin/administration & dosage
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Esophageal Neoplasms/*drug therapy/mortality/pathology
MH  - Esophagogastric Junction/*pathology
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stomach Neoplasms/*drug therapy/mortality/pathology
MH  - Treatment Outcome
PMC - PMC4544634
EDAT- 2014/02/22 06:00
MHDA- 2015/08/08 06:00
PMCR- 2014/02/21
CRDT- 2014/02/22 06:00
PHST- 2013/08/07 00:00 [received]
PHST- 2014/02/01 00:00 [accepted]
PHST- 2014/02/22 06:00 [entrez]
PHST- 2014/02/22 06:00 [pubmed]
PHST- 2015/08/08 06:00 [medline]
PHST- 2014/02/21 00:00 [pmc-release]
AID - 351 [pii]
AID - 10.1007/s10120-014-0351-5 [doi]
PST - ppublish
SO  - Gastric Cancer. 2015 Jan;18(1):168-76. doi: 10.1007/s10120-014-0351-5. Epub 2014 
      Feb 21.